Autoantibodies and Cardiomyopathy: Focus on Beta-1 Adrenergic Receptor Autoantibodies.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
21
10
2021
accepted:
16
03
2022
pubmed:
25
3
2022
medline:
9
9
2022
entrez:
24
3
2022
Statut:
epublish
Résumé
Antibody response to self-antigens leads to autoimmune response that plays a determinant role in cardiovascular disease outcomes including dilated cardiomyopathy (DCM). Although the origins of the self-reactive endogenous autoantibodies are not well-characterized, it is believed to be triggered by tissue injury or dysregulated humoral response. Autoantibodies that recognize G protein-coupled receptors are considered consequential because they act as modulators of downstream receptor signaling displaying a wide range of unique pharmacological properties. These wide range of pharmacological properties exhibited by autoantibodies has cellular consequences that is associated with progression of disease including DCM. Increase in autoantibodies recognizing beta-1 adrenergic receptor (β1AR), a G protein-coupled receptor critical for cardiac function, is observed in patients with DCM. Cellular and animal model studies have indicated pathological roles for the β1AR autoantibodies but less is understood about the molecular basis of their modulatory effects. Despite the recognition that β1AR autoantibodies could mediate deleterious outcomes, emerging evidence suggests that not all β1AR autoantibodies are deleterious. Recent clinical studies show that β1AR autoantibodies belonging to the IgG3 subclass is associated with beneficial cardiac outcomes in patients. This suggests that our understanding on the roles the β1AR autoantibodies play in mediating outcomes is not well-understood. Technological advances including structural determinants of antibody binding could provide insights on the modulatory capabilities of β1AR autoantibodies in turn, reflecting their diversity in mediating β1AR signaling response. In this study, we discuss the significance of the diversity in signaling and its implications in pathology.
Identifiants
pubmed: 35323150
doi: 10.1097/FJC.0000000000001264
pii: 00005344-202209000-00005
pmc: PMC9452444
mid: NIHMS1791518
doi:
Substances chimiques
Autoantibodies
0
Receptors, Adrenergic, beta-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-363Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL089473
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128382
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18:716–724.
Nemazee D. Mechanisms of central tolerance for B cells. Nat Rev Immunol. 2017;17:281–294.
Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–2767.
Blair PA, Norena LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010;32:129–140.
Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85:1734–1742.
Goldman JH, Keeling PJ, Warraich RS, et al. Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy. Br Heart J. 1995;74:598–603.
Riemekasten G, Philippe A, Näther M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70:530–536.
LaMarca B, Wallukat G, Llinas M, et al. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension. 2008;52:1168–1172.
Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14:855–862.
Jahns R, Boivin V, Hein L, et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429.
Shyu KG, Liou JY, Wang BW, et al. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12:409–420.
Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206–212.
Feldman DS, Carnes CA, Abraham WT, et al. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005;2:475–483.
Krumm B, Roth BL. A structural understanding of class B GPCR selectivity and activation revealed. Structure. 2020;28:277–279.
Wacker D, Stevens RC, Roth BL. How ligands illuminate GPCR molecular pharmacology. Cell. 2017;170:414–427.
Alexander SP, Davenport AP, Kelly E, et al. The concise guide to pharmacology 2015/16: G protein-coupled receptors. Br J Pharmacol. 2015;172:5744–5869.
Alexander SP, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2017/18: G protein-coupled receptors. Br J Pharmacol. 2017;174(suppl 1):S17–S129.
Alexander SP, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br J Pharmacol. 2021;178(suppl 1):S27–S156.
Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2019/20: G protein-coupled receptors. Br J Pharmacol. 2019;176(suppl 1):S21–S141.
Fu ML, Herlitz H, Schulze W, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 2000;18:945–953.
Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101:2382–2387.
Dechend R, Viedt C, Müller DN, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632–1639.
Velloso EP, Pimentel RL, Braga JF, et al. Identification of a novel agonist-like autoantibody in preeclamptic patients. Am J Hypertens. 2016;29:405–412.
Coesmans M, Smitt PA, Linden DJ, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol. 2003;53:325–336.
Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945–952.
Wallukat G, Müller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med. 2002;347:1806.
Wallukat G, Wollenberger A, Morwinski R, et al. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol. 1995;27:397–406.
Skiba MA, Kruse AC. Autoantibodies as endogenous modulators of GPCR signaling. Trends Pharmacol Sci. 2021;42:135–150.
Cabral-Marques O, Marques A, Giil LM, et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat Commun. 2018;9:5224.
Wallukat G, Jandrig B, Kunze R, et al. Autoantibodies directed against the endothelin A receptor in patients with benign prostatic hyperplasia. Prostate. 2017;77:458–465.
Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016;387:999–1011.
Liao L, Sindhwani R, Rojkind M, et al. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med. 1995;181:1123–1131.
Nagatomo Y, Tang WH. Autoantibodies and cardiovascular dysfunction: cause or consequence? Curr Heart Fail Rep. 2014;11:500–508.
Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477–1483.
Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991;147:2141–2147.
Lauer B, Schannwell M, Kühl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol. 2000;35:11–18.
Göser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. 2006;114:1693–1702.
Doesch AO, Mueller S, Nelles M, et al. Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy. Basic Res Cardiol. 2011;106:25–35.
Miettinen KH, Eriksson S, Magga J, et al. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail. 2008;14:481–488.
Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993;91:1964–1968.
Baba A, Yoshikawa T, Fukuda Y, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J. 2004;25:1108–1115.
Yoshizawa A, Nagai S, Baba Y, et al. Autoimmunity against M(2)muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype. Eur J Immunol. 2012;42:1152–1163.
Matsui S, Fu ML, Hayase M, et al. Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001;38(suppl 1):S43–S49.
Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 1997;29:641–655.
Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res. 1989;64:97–103.
Iwata M, Yoshikawa T, Baba A, et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res. 2001;88:578–586.
Fukuda Y, Miyoshi S, Tanimoto K, et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol. 2004;43:1090–1100.
Del Corsso C, de Carvalho AC, Martino HF, et al. Sera from patients with idiopathic dilated cardiomyopathy decrease ICa in cardiomyocytes isolated from rabbits. Am J Physiol Heart Circ Physiol. 2004;287:H1928–H1936.
Youker KA, Assad-Kottner C, Cordero-Reyes AM, et al. High proportion of patients with end-stage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. Eur Heart J. 2014;35:1061–1068.
Jahns R, Boivin V, Lohse MJ. beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med. 2006;16:20–24.
Staudt A, Mobini R, Fu M, et al. beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol. 2001;423:115–119.
Bornholz B, Weidtkamp-Peters S, Schmitmeier S, et al. Impact of human autoantibodies on beta1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res. 2013;97:472–480.
Jahns R, Boivin V, Krapf T, et al. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol. 2000;36:1280–1287.
Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999;99:649–654.
Nagatomo Y, McNamara DM, Alexis JD, et al. Myocardial recovery in patients with systolic heart failure and autoantibodies against beta1-adrenergic receptors. J Am Coll Cardiol. 2017;69:968–977.
Nagatomo Y, Li D, Kirsop J, et al. Autoantibodies specifically against beta1 adrenergic receptors and adverse clinical outcome in patients with chronic systolic heart failure in the beta-blocker era: the importance of immunoglobulin G3 subclass. J Card Fail. 2016;22:417–422.
Liu HR, Zhao RR, Zhi JM, et al. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity. 1999;29:43–51.
Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol. 2010;28:185–210.
Alsenz J, Kansy M. High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev. 2007;59:546–567.
Fleire SJ, Goldman JP, Carrasco YR, et al. B cell ligand discrimination through a spreading and contraction response. Science. 2006;312:738–741.
Gupta N, Wollscheid B, Watts JD, et al. Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat Immunol. 2006;7:625–633.
Gil D, Schamel WW, Montoya M, et al. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell. 2002;109:901–912.
Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777–1789.
Richards DM, Kyewski B, Feuerer M. Re-examining the nature and function of self-reactive T cells. Trends Immunol. 2016;37:114–125.
Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering and beyond. Nat Immunol. 2006;7:803–809.
Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest. 2004;114:1198–1208.
Wu Y, Zheng Z, Jiang Y, et al. The specificity of T cell regulation that enables self-nonself discrimination in the periphery. Proc Natl Acad Sci U S A. 2009;106:534–539.
Jiang H, Chess L. Qa-1/HLA-E-restricted regulatory CD8+ T cells and self-nonself discrimination: an essay on peripheral T-cell regulation. Hum Immunol. 2008;69:721–727.
Jiang H, Chess L. How the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol. 2009;102:95–133.
Ju YJ, Lee SW, Kye YC, et al. Self-reactivity controls functional diversity of naive CD8(+) T cells by co-opting tonic type I interferon. Nat Commun. 2021;12:6059.
Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol. 2011;12:478–484.
Hartley SB, Crosbie J, Brink R, et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991;353:765–769.
Russell DM, Dembić Z, Morahan G, et al. Peripheral deletion of self-reactive B cells. Nature. 1991;354:308–311.
Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med. 1993;177:1009–1020.
Jane-wit D, Altuntas CZ, Johnson JM, et al. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation. 2007;116:399–410.
Bouhlal H, Hocini H, Quillent-Grégoire C, et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol. 2001;166:7606–7611.
Lopalco L, Barassi C, Pastori C, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol. 2000;164:3426–3433.
Bomsel M, Pastori C, Tudor D, et al. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. AIDS. 2007;21:13–22.
Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood. 2004;104:2205–2206.
Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4:491–498.
Berkowska MA, Driessen GJ, Bikos V, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood. 2011;118:2150–2158.
Ferrari I, Levin MJ, Wallukat G, et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med. 1995;182:59–65.
Smulski C, Labovsky V, Levy G, et al. Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2beta protein and the human beta1 adrenergic receptor. FASEB J. 2006;20:1396–1406.
Mahler E, Sepulveda P, Jeannequin O, et al. A monoclonal antibody against the immunodominant epitope of the ribosomal P2beta protein of Trypanosoma cruzi interacts with the human beta 1-adrenergic receptor. Eur J Immunol. 2001;31:2210–2216.
Gil-Cruz C, Perez-Shibayama C, De Martin A, et al. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019;366:881–886.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
Pan Q, Hammarström L. Molecular basis of IgG subclass deficiency. Immunol Rev. 2000;178:99–110.
Jefferis R, Kumararatne DS. Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol. 1990;81:357–367.
Pone EJ, Zan H, Zhang J, et al. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit Rev Immunol. 2010;30:1–29.
Michaelsen TE, Naess LM, Aase A. Human IgG3 is decreased and IgG1, IgG2 and IgG4 are unchanged in molecular size by mild reduction and reoxidation without any major change in effector functions. Mol Immunol. 1993;30:35–45.
Saluk PH, Clem LW. The unique molecular weight of the heavy chain from human IgG3. J Immunol. 1971;107:298–301.
Staudt A, Dörr M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J. 2005;150:729–736.
Warraich RS, Noutsias M, Kazak I, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J. 2002;143:1076–1084.
Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 1997;159:3372–3382.
Warraich RS, Griffiths E, Falconar A, et al. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. FASEB J. 2006;20:651–660.
Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol. 2002;39:646–652.
Braun N, Gutenberger S, Erley CM, et al. Immunoglobulin and circulating immune complex kinetics during immunoadsorption onto protein A sepharose. Transfus Sci. 1998;19(suppl):25–31.
Nagatomo Y, Baba A, Ito H, et al. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J Clin Apher. 2011;26:1–8.
Hirata N, Kuriyama T, Yamawaki N. Immusorba TR and PH. Ther Apher Dial. 2003;7:85–90.
Briles DE, Claflin JL, Schroer K, et al. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature. 1981;294:88–90.
Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J. 1990;9:S16–S24.
Beard LJ, Ferris L, Ferrante A. Immunoglobulin G subclasses and lymphocyte subpopulations and function in osteomyelitis and septic arthritis. Acta Paediatr Scand. 1990;79:599–604.
Eftekhari P, Sallé L, Lezoualc'h F, et al. Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol. 2000;30:2782–2790.
Zimering MB, Nadkarni SG. Schizophrenia plasma autoantibodies promote biased agonism at the 5-hydroxytryptamine 2A receptor: neurotoxicity is positively modulated by metabotropic glutamate 2/3 receptor agonism. Endocrinol Diabetes Metab J. 2019;3:1–10.
Borda T, Gomez R, Berría MI, et al. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia. 2004;45:144–154.
Borda T, Perez Rivera R, Joensen L, et al. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol. 2002;168:3667–3674.
Bian J, Lei J, Yin X, et al. Limited AT1 receptor internalization is a novel mechanism underlying sustained vasoconstriction induced by AT1 receptor autoantibody from preeclampsia. J Am Heart Assoc. 2019;8:e011179.
Venter JC, Fraser CM, Harrison LC. Autoantibodies to beta 2-adrenergic receptors: a possible cause of adrenergic hyporesponsiveness in allergic rhinitis and asthma. Science. 1980;207:1361–1363.
Fraser CM, Venter JC, Kaliner M. Autonomic abnormalities and autoantibodies to beta-adrenergic receptors. N Engl J Med. 1981;305:1165–1170.
Christ T, Wettwer E, Dobrev D, et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol. 2001;33:1515–1525.
Cao N, Chen H, Bai Y, et al. beta2-adrenergic receptor autoantibodies alleviated myocardial damage induced by beta1-adrenergic receptor autoantibodies in heart failure. Cardiovasc Res. 2018;114:1487–1498.
Wallukat G, Fu HM, Matsui S, et al. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects. Life Sci. 1999;64:465–469.
Hong CM, Zheng QS, Liu XT, et al. Effects of autoantibodies against M2 muscarinic acetylcholine receptors on rabbit atria in vivo. Cardiology. 2009;112:180–187.
Peter JC, Nicholson JR, Heydet D, et al. Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol. 2007;292:R2151–R2158.
Wolfel A, Sattele M, Zechmeister C, et al. Unmasking features of the auto-epitope essential for beta1 -adrenoceptor activation by autoantibodies in chronic heart failure. ESC Heart Fail. 2020;7:1830–1841.
Morshed SA, Ando T, Latif R, et al. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Endocrinology. 2010;151:5537–5549.
Sanders J, Chirgadze DY, Sanders P, et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid. 2007;17:395–410.
Sanders P, Young S, Sanders J, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. 2011;46:81–99.
Schimke I, Müller J, Dandel M, et al. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher. 2005;20:137–142.
Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118:S94–S105.
Jahns R, Boivin V, Siegmund C, et al. Activating beta-1-adrenoceptor antibodies are not associated with cardiomyopathies secondary to valvular or hypertensive heart disease. J Am Coll Cardiol. 1999;34:1545–1551.
Nikolaev VO, Boivin V, Störk S, et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol. 2007;50:423–431.
Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010;9:373–386.
Chiale PA, Ferrari I, Mahler E, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation. 2001;103:1765–1771.
Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev. 2021;26:1–19.
Bondue A, Arbustini E, Bianco A, et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res. 2018;114:1287–1303.
Insel PA, Hammond HK. Beta-adrenergic receptors in heart failure. J Clin Invest. 1993;92:2564.
Podlowski S, Luther HP, Morwinski R, et al. Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation. 1998;98:2470–2476.
Tutor AS, Penela P, Mayor F Jr. Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res. 2007;76:51–60.
Wei H, Ahn S, Barnes WG, et al. Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2. J Biol Chem. 2004;279:48255–48261.
Ahn S, Shenoy SK, Wei H, et al. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem. 2004;279:35518–35525.
Ahn S, Wei H, Garrison TR, et al. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J Biol Chem. 2004;279:7807–7811.
Mohan ML, Nagatomo Y, Saha PP, et al. The IgG3 subclass of beta1-adrenergic receptor autoantibodies is an endogenous biaser of beta1AR signaling. Mol Biol Cell. 2021;32:622–633.
Rapacciuolo A, Suvarna S, Barki-Harrington L, et al. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem. 2003;278:35403–35411.
Kim IM, Tilley DG, Chen J, et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008;105:14555–14560.
Tilley DG, Kim IM, Patel PA, et al. Beta-arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem. 2009;284:20375–20386.
Pani B, Ahn S, Rambarat PK, et al. Unique positive cooperativity between the beta-arrestin-biased beta-blocker carvedilol and a small molecule positive allosteric modulator of the beta2-adrenergic receptor. Mol Pharmacol. 2021;100:513–525.
Wang J, Pani B, Gokhan I, et al. Beta-arrestin-biased allosteric modulator potentiates carvedilol-stimulated beta adrenergic receptor cardioprotection. Mol Pharmacol. 2021;100:568–579.
Ma N, Nivedha AK, Vaidehi N. Allosteric communication regulates ligand-specific GPCR activity. FEBS J. 2021;288:2502–2512.
Munch G, Boivin-Jahns V, Holthoff HP, et al. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012;14:1230–1239.
Nnane IP, Plotnikov AH, Peters G, et al. Pharmacokinetics and safety of single intravenous doses of JNJ-54452840, an anti-beta1-adrenergic receptor antibody cyclopeptide, in healthy male Japanese and caucasian participants. Clin Pharmacokinet. 2016;55:225–236.
Boivin V, Beyersdorf N, Palm D, et al. Novel receptor-derived cyclopeptides to treat heart failure caused by anti-beta1-adrenoceptor antibodies in a human-analogous rat model. PLoS One. 2015;10:e0117589.